Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans
Like native DOPA, [18F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([18F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation and elimination of [18F]FDOPA metabolites, plasma from human subjects undergoing positron emission tomographic (PET) studies was analyzed by h...
Saved in:
Published in | Journal of cerebral blood flow and metabolism Vol. 13; no. 4; pp. 668 - 675 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
London, England
SAGE Publications
01.07.1993
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Like native DOPA, [18F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([18F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation and elimination of [18F]FDOPA metabolites, plasma from human subjects undergoing positron emission tomographic (PET) studies was analyzed by high-performance liquid chromatography (HPLC). In addition to the principal metabolite O-methyl-[18F]FDOPA (OMe-[18F]FDOPA), two decarboxylated metabolites were detected in plasma from carbidopa pretreated subjects. The concentrations of each metabolite during 90 min following tracer injection could be described as a function of the concentration of [18F]FDOPA, and two rate constants; k0, the rate of formation, and k–1, the rate of clearance. Plasma metabolite time series generated from total plasma activity curves and measured rate constants were in close agreement with the actual concentrations determined by HPLC fractionation. Population means for k0 (0.011 ± 0.002 min−1) and k–1, (0.010 ± 0.003 min−1) were used to generate “simulated” plasma curves. The measured and generated plasma curves were used as inputs for estimation of partition and decarboxylation coefficients of [18F]FDOPA in brain. The use of generated input functions from normal population means of transfer coefficients did not introduce a systematic error into the estimate of the enzyme activity. However, the high variability of these estimates in patients precludes the use of this technique as an alterative to individual HPLC measurements. |
---|---|
AbstractList | Like native DOPA, [ 18 F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([ 18 F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation and elimination of [ 18 F]FDOPA metabolites, plasma from human subjects undergoing positron emission tomographic (PET) studies was analyzed by high-performance liquid chromatography (HPLC). In addition to the principal metabolite O-methyl-[ 18 F]FDOPA (OMe-[ 18 F]FDOPA), two decarboxylated metabolites were detected in plasma from carbidopa pretreated subjects. The concentrations of each metabolite during 90 min following tracer injection could be described as a function of the concentration of [ 18 F]FDOPA, and two rate constants; k 0 , the rate of formation, and k –1 , the rate of clearance. Plasma metabolite time series generated from total plasma activity curves and measured rate constants were in close agreement with the actual concentrations determined by HPLC fractionation. Population means for k 0 (0.011 ± 0.002 min −1 ) and k –1 , (0.010 ± 0.003 min −1 ) were used to generate “simulated” plasma curves. The measured and generated plasma curves were used as inputs for estimation of partition and decarboxylation coefficients of [ 18 F]FDOPA in brain. The use of generated input functions from normal population means of transfer coefficients did not introduce a systematic error into the estimate of the enzyme activity. However, the high variability of these estimates in patients precludes the use of this technique as an alterative to individual HPLC measurements. Like native DOPA, [18F]-6-fluoro-L-3,4-dihydroxyphenylalanine ([18F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation and elimination of [18F]FDOPA metabolites, plasma from human subjects undergoing positron emission tomographic (PET) studies was analyzed by high-performance liquid chromatography (HPLC). In addition to the principal metabolite O-methyl-[18F]FDOPA (OMe[18F]FDOPA), two decarboxylated metabolites were detected in plasma from carbidopa pretreated subjects. The concentrations of each metabolite during 90 min following tracer injection could be described as a function of the concentration of [18F]FDOPA, and two rate constants; k0, the rate of formation, and k-1, the rate of clearance. Plasma metabolite time series generated from total plasma activity curves and measured rate constants were in close agreement with the actual concentrations determined by HPLC fractionation. Population means for k0 (0.011 +/- 0.002 min-1) and k-1 (0.010 +/- 0.003 min-1) were used to generate "simulated" plasma curves. The measured and generated plasma curves were used as inputs for estimation of partition and decarboxylation coefficients of [18F]FDOPA in brain. The use of generated input functions from normal population means of transfer coefficients did not introduce a systematic error into the estimate of the enzyme activity. However, the high variability of these estimates in patients precludes the use of this technique as an alterative to individual HPLC measurements. Like native DOPA, [18F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([18F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation and elimination of [18F]FDOPA metabolites, plasma from human subjects undergoing positron emission tomographic (PET) studies was analyzed by high-performance liquid chromatography (HPLC). In addition to the principal metabolite O-methyl-[18F]FDOPA (OMe-[18F]FDOPA), two decarboxylated metabolites were detected in plasma from carbidopa pretreated subjects. The concentrations of each metabolite during 90 min following tracer injection could be described as a function of the concentration of [18F]FDOPA, and two rate constants; k0, the rate of formation, and k–1, the rate of clearance. Plasma metabolite time series generated from total plasma activity curves and measured rate constants were in close agreement with the actual concentrations determined by HPLC fractionation. Population means for k0 (0.011 ± 0.002 min−1) and k–1, (0.010 ± 0.003 min−1) were used to generate “simulated” plasma curves. The measured and generated plasma curves were used as inputs for estimation of partition and decarboxylation coefficients of [18F]FDOPA in brain. The use of generated input functions from normal population means of transfer coefficients did not introduce a systematic error into the estimate of the enzyme activity. However, the high variability of these estimates in patients precludes the use of this technique as an alterative to individual HPLC measurements. |
Author | Gjedde, Albert Léger, Gabriel C. Kuwabara, Hiroto Cumming, Paul |
Author_xml | – sequence: 1 givenname: Paul surname: Cumming fullname: Cumming, Paul organization: Positron Imaging Laboratories, McConnell Brain Imaging Center, Montreal Neurological Institute, Montreal, Canada – sequence: 2 givenname: Gabriel C. surname: Léger fullname: Léger, Gabriel C. organization: Positron Imaging Laboratories, McConnell Brain Imaging Center, Montreal Neurological Institute, Montreal, Canada – sequence: 3 givenname: Hiroto surname: Kuwabara fullname: Kuwabara, Hiroto organization: Positron Imaging Laboratories, McConnell Brain Imaging Center, Montreal Neurological Institute, Montreal, Canada – sequence: 4 givenname: Albert surname: Gjedde fullname: Gjedde, Albert organization: Positron Imaging Laboratories, McConnell Brain Imaging Center, Montreal Neurological Institute, Montreal, Canada |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/8314919$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kM9PwjAYhhuDQUCPHk12MmostnT9dSQgYkICB01M1DTt1slwW7Flifz3DiHePH2H9_nefN_TBa3KVRaAc4z6GBFxt0pMVvaxlKQv6BHoYEol5AizFuigAceQcfFyArohrBBCglDaBm1BcCyx7IC3xVL7UifuM6_sJk9C5LJoUehQ6ojBVywm75Oidt7BApLbGI7z5Tb17nu7XtpqW-hCV81idLUnx_PF8DrKq2hal7oKp-A400WwZ4fZA8-T-6fRFM7mD4-j4Qwm8UBsoKSYsYxSRLjVTGidEC4FjSk1zGKKUmMQi42JjU4MoZbHsUiR5cYSk2qGSA9c7nvX3n3VNmxUmYfEFs1x1tVBccqlpINBA8I9mHgXgreZWvu81H6rMFI7m-rXptrZVII2_MWhuDalTf_og74mv9nnQX9YtXK1r5o__yn7AbfNfwQ |
CitedBy_id | crossref_primary_10_1016_0006_2952_95_00216_M crossref_primary_10_1002_syn_10034 crossref_primary_10_1007_s11682_021_00509_5 crossref_primary_10_1016_j_neuroimage_2007_12_045 crossref_primary_10_1016_0024_3205_95_00147_X crossref_primary_10_1177_0271678X15610585 crossref_primary_10_1111_j_1600_0404_2004_00299_x crossref_primary_10_1002_syn_22029 crossref_primary_10_1038_s41380_018_0042_4 crossref_primary_10_1523_JNEUROSCI_0805_07_2007 crossref_primary_10_1111_j_1749_6632_1997_tb48637_x crossref_primary_10_1016_j_biopsych_2018_07_003 crossref_primary_10_1016_j_neurobiolaging_2008_05_005 crossref_primary_10_1371_journal_pone_0073903 crossref_primary_10_1523_JNEUROSCI_1560_14_2014 crossref_primary_10_1016_j_pscychresns_2019_07_005 crossref_primary_10_1038_npp_2014_87 crossref_primary_10_1038_s41380_021_01108_y crossref_primary_10_2217_npy_11_51 crossref_primary_10_1016_j_neuroimage_2009_11_035 crossref_primary_10_1038_s41598_017_16020_1 crossref_primary_10_1111_j_1471_4159_1993_tb13651_x crossref_primary_10_3390_ijms22041645 crossref_primary_10_1016_S0165_0270_01_00453_8 crossref_primary_10_3727_000000002783985314 crossref_primary_10_1038_sj_npp_1300103 crossref_primary_10_1093_brain_awz093 crossref_primary_10_1038_s41380_019_0570_6 crossref_primary_10_1097_00004647_199711000_00014 crossref_primary_10_1001_jamapsychiatry_2017_2943 crossref_primary_10_1002__SICI_1098_2396_199712_27_4_336__AID_SYN7_3_0_CO_2_D crossref_primary_10_1016_j_biopsych_2012_11_017 crossref_primary_10_1034_j_1600_0404_2001_103005309_x crossref_primary_10_1007_s00213_014_3523_4 crossref_primary_10_1016_j_nucmedbio_2020_01_001 crossref_primary_10_1038_jcbfm_2013_29 crossref_primary_10_1002_hbm_20325 crossref_primary_10_1093_schbul_sbaa128 crossref_primary_10_1038_sj_jcbfm_9600202 crossref_primary_10_7554_eLife_29088 crossref_primary_10_2967_jnumed_114_145565 crossref_primary_10_1002__SICI_1098_2396_199812_30_4_351__AID_SYN2_3_0_CO_2_2 crossref_primary_10_1016_S0969_8051_00_00187_6 crossref_primary_10_1016_S0014_2999_97_01157_6 crossref_primary_10_1016_j_neuroimage_2005_11_014 crossref_primary_10_1002__SICI_1098_2396_19990915_33_4_247__AID_SYN1_3_0_CO_2_6 crossref_primary_10_1016_S0006_8993_97_00552_0 crossref_primary_10_1186_s13550_023_01049_3 crossref_primary_10_1523_JNEUROSCI_1398_13_2013 crossref_primary_10_1002__SICI_1098_2396_199805_29_1_37__AID_SYN4_3_0_CO_2_C crossref_primary_10_1038_tp_2016_270 crossref_primary_10_1016_S0736_5748_98_00017_3 crossref_primary_10_1038_sj_jcbfm_9600079 crossref_primary_10_1017_S0033291716002051 crossref_primary_10_1016_j_neuroimage_2009_12_058 crossref_primary_10_1016_S0165_0270_97_00094_0 crossref_primary_10_1177_096368970000900210 crossref_primary_10_1177_02698811221122031 crossref_primary_10_1002_1098_2396_200008_37_2_81__AID_SYN1_3_0_CO_2 crossref_primary_10_1016_0969_8051_95_02083_7 crossref_primary_10_1002_syn_1077 crossref_primary_10_1016_j_biopsych_2013_05_027 crossref_primary_10_1038_s41386_020_0740_x crossref_primary_10_1002_syn_1071 crossref_primary_10_1016_j_cpet_2013_08_003 crossref_primary_10_1177_1073858409338217 crossref_primary_10_1097_00004647_199910000_00011 crossref_primary_10_1038_s41386_020_00866_7 |
Cites_doi | 10.1073/pnas.88.7.2721 10.1016/0006-2952(72)90392-9 10.1016/0006-2952(87)90526-0 10.1212/WNL.42.1.199 10.1038/jcbfm.1993.7 10.1038/317246a0 10.1002/cpt1972134584 10.1038/252237a0 10.1159/000116170 10.1016/0006-8993(91)90037-V 10.1016/0006-2952(90)90601-G 10.1016/0024-3205(90)90228-J 10.1038/jcbfm.1990.124 10.1212/WNL.34.2.198 10.1016/0024-3205(86)90403-0 10.1212/WNL.40.1.156 10.1038/jcbfm.1991.129 10.1111/j.1471-4159.1987.tb04135.x 10.1038/jcbfm.1991.155 10.1038/305137a0 10.1212/WNL.17.5.427 10.1097/00002826-199012000-00006 10.1016/0006-2952(88)90725-3 |
ContentType | Journal Article |
Copyright | 1993 International Society for Cerebral Blood Flow and Metabolism |
Copyright_xml | – notice: 1993 International Society for Cerebral Blood Flow and Metabolism |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1038/jcbfm.1993.85 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry |
EISSN | 1559-7016 |
EndPage | 675 |
ExternalDocumentID | 10_1038_jcbfm_1993_85 8314919 10.1038_jcbfm.1993.85 |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GroupedDBID | --- -Q- -TM .55 .GJ 0R~ 29K 2WC 36B 39C 3O- 3V. 4.4 53G 54M 5GY 5RE 5VS 70F 7X7 88A 88E 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 AABMB AACKU AACMV AADUE AAEWN AAGGD AAGMC AAJIQ AAJPV AAKGS AAMGE AANSI AAPEO AAQGT AAQXH AARDL AARIX AATAA AATBZ AAUAS AAVDI AAXOT AAYTG AAZBJ ABAWP ABAWZ ABCCA ABDWY ABEIX ABFWQ ABHKI ABJNI ABKRH ABLUO ABNCE ABPGX ABPNF ABQKF ABQNX ABQXT ABRHV ABUWG ABVFX ABXGC ABYTW ACARO ACDSZ ACDXX ACFEJ ACFMA ACGBL ACGFO ACGFS ACGZU ACJTF ACLFY ACLHI ACNXM ACOFE ACOXC ACPRK ACROE ACSIQ ACTQU ACUAV ACUIR ACXKE ACXMB ADBBV ADEIA ADMPF ADRRZ ADTBJ ADUKL ADZZY AECGH AENEX AEPTA AEQLS AESZF AEUHG AEUIJ AEWDL AEWHI AEXFG AEXNY AFEET AFFNX AFFZS AFKRA AFKRG AFMOU AFOSN AFQAA AFUIA AGKLV AGNHF AGWFA AHMBA AIGRN AIOMO AJABX AJEFB AJMMQ AJSCY AJUZI AJXAJ ALIPV ALMA_UNASSIGNED_HOLDINGS ALTZF AMCVQ ANDLU AOIJS ARTOV AUTPY AYAKG B8M BAWUL BBNVY BBRGL BDDNI BENPR BHPHI BKIIM BKSCU BPACV BPHCQ BSEHC BVXVI BWJAD C45 CAG CBRKF CCPQU CDWPY CFDXU COF CORYS CQQTX CS3 CUTAK D-I DC- DC. DIK DOPDO DV7 E3Z EBS EE. EJD EMOBN F5P FHBDP FYUFA GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION GX1 HCIFZ HMCUK HYE HZ~ J8X JCYGO JSO K.F KQ8 LK8 M0L M1P M4V M7P O9- OK1 OVD P2P P6G PQQKQ PROAC PSQYO Q1R Q2X RNS RNTTT ROL RPM SCNPE SFC SHG SPQ SPV TEORI TR2 UKHRP W2D X7M YFH YOC ZGI ZONMY ZPPRI ZRKOI ZSSAH ZXP ACJER AFVCE AJXGE ALKWR CGR CUY CVF ECM EIF H13 NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c428t-95166f55037ea68aac37985455b6e150dbb064bb4bacb35e7448d0e7be3bda603 |
ISSN | 0271-678X |
IngestDate | Fri Aug 16 10:28:05 EDT 2024 Wed Sep 11 13:45:53 EDT 2024 Tue Oct 15 23:16:12 EDT 2024 Tue Jul 16 20:52:30 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | O-Methyl-6-[18F]fluoro-l-DOPA Metabolism Positron emission tomography Modeling 6-[18F]Fluoro-l-DOPA |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c428t-95166f55037ea68aac37985455b6e150dbb064bb4bacb35e7448d0e7be3bda603 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://journals.sagepub.com/doi/pdf/10.1038/jcbfm.1993.85 |
PMID | 8314919 |
PQID | 75799522 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_75799522 crossref_primary_10_1038_jcbfm_1993_85 pubmed_primary_8314919 sage_journals_10_1038_jcbfm_1993_85 |
PublicationCentury | 1900 |
PublicationDate | 1993-07-01 |
PublicationDateYYYYMMDD | 1993-07-01 |
PublicationDate_xml | – month: 07 year: 1993 text: 1993-07-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | London, England |
PublicationPlace_xml | – name: London, England – name: United States |
PublicationTitle | Journal of cerebral blood flow and metabolism |
PublicationTitleAlternate | J Cereb Blood Flow Metab |
PublicationYear | 1993 |
Publisher | SAGE Publications |
Publisher_xml | – name: SAGE Publications |
References | Garnett, Firnau, Nahmias 1983; 305 Da Prada, Kettler, Zrcher, Schnaffner, Haefely 1987; 27 Cedarbaum, Léger, Reches, Guttman 1990; 6 Cumming, Hausser, Martin, Grierson, Adam, Ruth, McGeer 1988; 37 Doudet, McLellan, Carson, Adams, Miyake, Aigner, Finn, Cohen 1991; 11 Kuwabara, Cumming, Reith, Léger, Diksic, Evans, Gjedde 1993; 13 Cumming, Boyes, Martin, Adam, Ruth, McGeer 1987a; 48 Boyes, Cumming, Martin, McGeer 1986; 39 Calne, Langsten, Martin, Stoessl, Ruth, Adam, Schulzer 1985; 317 Jenner, Rose 1974; 252 Reith, Dyve, Kuwabara, Guttman, Diksic, Gjedde 1990; 10 Hoehn, Yahr 1967; 17 Léger, Guttman, Leblanc, Cedarbaum, Gjedde, Reches 1990; 40 Melega, Hoffman, Luxen, Nissenson, Phelps, Barrio 1990b; 47 Guldberg, Marsden 1975; 27 Huang, Yu, Barrio, Grafton, Melega, Hoffman, Satyamurthy, Mazziotta, Phelps 1991; 11 Bianchine, Messiha, Hsu 1973; 13 Ward, Trombley, Calne, Kopin 1984; 34 Doller, Connor, Lock, Sloviter, Dvorchik, Vesell 1978; 6 Melega, Hoffman, Schneider, Phelps, Barrio 1991; 543 Goodall, Alton 1972; 21 Melega, Luxen, Perlmutter, Nissenson, Phelps, Barrio 1990a; 39 Laihinen, Rinne, Rinne, Haaparanta, Ruotsalainen, Bergman, Solin 1992; 42 Cumming, Boyes, Martin, Adam, Ruth, McGeer 1987b; 36 Gjedde, Reith, Dyve, Léger, Guttman, Diksic, Evans, Kuwabara 1991; 88 bibr22-jcbfm.1993.85 bibr6-jcbfm.1993.85 Guldberg HC (bibr14-jcbfm.1993.85) 1975; 27 bibr1-jcbfm.1993.85 bibr16-jcbfm.1993.85 bibr8-jcbfm.1993.85 bibr3-jcbfm.1993.85 Doller JH (bibr9-jcbfm.1993.85) 1978; 6 bibr11-jcbfm.1993.85 Léger GC (bibr20-jcbfm.1993.85) 1990; 40 bibr18-jcbfm.1993.85 bibr24-jcbfm.1993.85 bibr5-jcbfm.1993.85 bibr7-jcbfm.1993.85 bibr23-jcbfm.1993.85 bibr13-jcbfm.1993.85 bibr15-jcbfm.1993.85 bibr21-jcbfm.1993.85 bibr12-jcbfm.1993.85 bibr2-jcbfm.1993.85 bibr17-jcbfm.1993.85 bibr10-jcbfm.1993.85 bibr4-jcbfm.1993.85 bibr19-jcbfm.1993.85 bibr25-jcbfm.1993.85 |
References_xml | – volume: 13 start-page: 43 year: 1993 end-page: 56 article-title: Human striatal l-DOPA decarboxylase activity estimated in vivo using 6-[ F]fluorodopa and positron emission tomography: Error analysis and application to normal subjects publication-title: J Cereb Blood Flow Metab contributor: fullname: Gjedde – volume: 37 start-page: 247 year: 1988 end-page: 250 article-title: Kinetics of in vitro decarboxylation and the in vivo metabolism of 2- and 6- F-fluorodopa in the hooded rat publication-title: Biochem Pharmacol contributor: fullname: McGeer – volume: 27 start-page: 9 year: 1987 end-page: 20 article-title: Inhibition of decarboxylase and levels of DOPA and 3- -methyldopa: A comparative study of benserazide versus carbidopa in rodents and of Madopar Standard versus Madopar HBS in volunteers publication-title: Eur Neurol contributor: fullname: Haefely – volume: 40 start-page: 156 year: 1990 article-title: Inhibition of 3- -methylfluorodopa formation with OR462: Attempts to simplify the fluorodopa model for PET analysis publication-title: Neurology contributor: fullname: Reches – volume: 21 start-page: 2,401 year: 1972 end-page: 2,408 article-title: Metabolism of 3,4-dihydroxyphenylalanine (l-DOPA) in human subjects publication-title: Biochem Pharmacol contributor: fullname: Alton – volume: 543 start-page: 271 year: 1991 end-page: 276 article-title: 6-[ F]Fluoro-l-DOPA metabolism in MPTP-treated monkeys: Assessment of tracer methodologies for positron emission tomography publication-title: Brain Res contributor: fullname: Barrio – volume: 11 start-page: 898 year: 1991 end-page: 913 article-title: Kinetics and modeling of l-6-[ F]fluoro-DOPA in human positron emission tomographic studies publication-title: J Cereb Blood Flow Metab contributor: fullname: Phelps – volume: 17 start-page: 472 year: 1967 end-page: 542 article-title: Parkinsonism: Onset, progression and mortality publication-title: Neurology contributor: fullname: Yahr – volume: 305 start-page: 137 year: 1983 end-page: 138 article-title: Dopamine visualized in the basal ganglia of living man publication-title: Nature contributor: fullname: Nahmias – volume: 317 start-page: 246 year: 1985 end-page: 248 article-title: Positron emission tomography after MPTP: Observations relating to the cause of Parkinson's disease publication-title: Nature contributor: fullname: Schulzer – volume: 252 start-page: 237 year: 1974 end-page: 238 article-title: Dopamine 3- -sulfate, an end product of l-DOPA metabolism in Parkinson patients publication-title: Nature contributor: fullname: Rose – volume: 13 start-page: 584 year: 1973 end-page: 594 article-title: Peripheral aromatic L-amino acid decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of l-2- C-DOPA publication-title: Clin Pharmacol Ther contributor: fullname: Hsu – volume: 42 start-page: 199 year: 1992 end-page: 203 article-title: [ F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462) publication-title: Neurology contributor: fullname: Solin – volume: 10 start-page: 707 year: 1990 end-page: 719 article-title: Blood-brain transfer and metabolism of 6-[ F]fluoro-l-dopa in rat publication-title: J Cereb Blood Flow Metab contributor: fullname: Gjedde – volume: 39 start-page: 1,853 year: 1990a end-page: 1,860 article-title: Comparative in vivo metabolism of 6-[ F]fluoro- -DOPA and [ H] -DOPA publication-title: Biochem Pharmacol contributor: fullname: Barrio – volume: 34 start-page: 198 year: 1984 end-page: 201 article-title: l-DOPA decarboxylation in chronically treated patients publication-title: Neurology contributor: fullname: Kopin – volume: 6 start-page: 544 year: 1990 end-page: 552 article-title: Effect of nitecapone (OR-462) on the pharmacokinetics of l-dopa and 3- -methyldopa formation in cynomolgus monkey publication-title: Clin Neuropharmacol contributor: fullname: Guttman – volume: 47 start-page: 149 year: 1990b end-page: 157 article-title: The effects of carbidopa on the metabolism of 6-[ F]fluoro-DOPA in rats, monkeys and humans publication-title: Life Sci contributor: fullname: Barrio – volume: 6 start-page: 164 year: 1978 end-page: 168 article-title: Levodopa pharmacokinetics: Alterations after benserazide, a decarboxylase inhibitor publication-title: Drug Metab Dispos contributor: fullname: Vesell – volume: 39 start-page: 2,243 year: 1986 end-page: 2,252 article-title: Determination of plasma [ F]-6-fluorodopa during positron emission tomography in carbidopa treated subjects publication-title: Life Sci contributor: fullname: McGeer – volume: 48 start-page: 601 year: 1987a end-page: 608 article-title: The metabolism of [ F]-6-fluoro-l-3,4-dihydroxyphenylalanine in the hooded rat publication-title: J Neurochem contributor: fullname: McGeer – volume: 11 start-page: 726 year: 1991 end-page: 734 article-title: Distribution and kinetics of 3- -methyl-6-[ F]fluoro-l-DOPA in the rhesus monkey brain publication-title: J Cereb Blood Flow Metab contributor: fullname: Cohen – volume: 27 start-page: 135 year: 1975 end-page: 188 article-title: Catechol- -methyltransferase: Pharmacological aspects and physiological role publication-title: Pharmacol Rev contributor: fullname: Marsden – volume: 36 start-page: 2,527 year: 1987b end-page: 2,531 article-title: Altered metabolism of [ F]-6-fluorodopa in the hooded rat following inhibition of catechol-) -methyltransferase with U-0521 publication-title: Biochem Pharmacol contributor: fullname: McGeer – volume: 88 start-page: 2,721 year: 1991 end-page: 2,725 article-title: Dopa decarboxylase activity of the living human brain publication-title: Proc Natl Acad Sci USA contributor: fullname: Kuwabara – volume: 6 start-page: 164 year: 1978 ident: bibr9-jcbfm.1993.85 publication-title: Drug Metab Dispos contributor: fullname: Doller JH – ident: bibr12-jcbfm.1993.85 doi: 10.1073/pnas.88.7.2721 – ident: bibr13-jcbfm.1993.85 doi: 10.1016/0006-2952(72)90392-9 – ident: bibr6-jcbfm.1993.85 doi: 10.1016/0006-2952(87)90526-0 – volume: 27 start-page: 135 year: 1975 ident: bibr14-jcbfm.1993.85 publication-title: Pharmacol Rev contributor: fullname: Guldberg HC – ident: bibr19-jcbfm.1993.85 doi: 10.1212/WNL.42.1.199 – ident: bibr18-jcbfm.1993.85 doi: 10.1038/jcbfm.1993.7 – ident: bibr3-jcbfm.1993.85 doi: 10.1038/317246a0 – ident: bibr1-jcbfm.1993.85 doi: 10.1002/cpt1972134584 – ident: bibr17-jcbfm.1993.85 doi: 10.1038/252237a0 – ident: bibr8-jcbfm.1993.85 doi: 10.1159/000116170 – ident: bibr23-jcbfm.1993.85 doi: 10.1016/0006-8993(91)90037-V – ident: bibr21-jcbfm.1993.85 doi: 10.1016/0006-2952(90)90601-G – ident: bibr22-jcbfm.1993.85 doi: 10.1016/0024-3205(90)90228-J – ident: bibr24-jcbfm.1993.85 doi: 10.1038/jcbfm.1990.124 – ident: bibr25-jcbfm.1993.85 doi: 10.1212/WNL.34.2.198 – ident: bibr2-jcbfm.1993.85 doi: 10.1016/0024-3205(86)90403-0 – volume: 40 start-page: 156 year: 1990 ident: bibr20-jcbfm.1993.85 publication-title: Neurology doi: 10.1212/WNL.40.1.156 contributor: fullname: Léger GC – ident: bibr10-jcbfm.1993.85 doi: 10.1038/jcbfm.1991.129 – ident: bibr5-jcbfm.1993.85 doi: 10.1111/j.1471-4159.1987.tb04135.x – ident: bibr16-jcbfm.1993.85 doi: 10.1038/jcbfm.1991.155 – ident: bibr11-jcbfm.1993.85 doi: 10.1038/305137a0 – ident: bibr15-jcbfm.1993.85 doi: 10.1212/WNL.17.5.427 – ident: bibr4-jcbfm.1993.85 doi: 10.1097/00002826-199012000-00006 – ident: bibr7-jcbfm.1993.85 doi: 10.1016/0006-2952(88)90725-3 |
SSID | ssj0008355 |
Score | 1.7121232 |
Snippet | Like native DOPA, [18F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([18F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation... Like native DOPA, [18F]-6-fluoro-L-3,4-dihydroxyphenylalanine ([18F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of formation... Like native DOPA, [ 18 F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([ 18 F]FDOPA) is subject to methylation and decarboxylation. To determine the rates of... |
SourceID | proquest crossref pubmed sage |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 668 |
SubjectTerms | Adult Arteries Carbidopa - pharmacology Chromatography, High Pressure Liquid Dihydroxyphenylalanine - analogs & derivatives Dihydroxyphenylalanine - blood Fluorine Radioisotopes Humans Parkinson Disease - blood Reference Values Tomography, Emission-Computed |
Title | Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans |
URI | https://journals.sagepub.com/doi/full/10.1038/jcbfm.1993.85 https://www.ncbi.nlm.nih.gov/pubmed/8314919 https://search.proquest.com/docview/75799522 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKEGIvCDYmyjUSbAINjySOnfRxDNqJm3jYpEoMRXbsQEeTTG0qVH49x5e0DVsl4CWq0sauzvfVPcf-zjkIPaM-50EUSNwLc6F3q3zMY59iRjMiaR4QZRJpP35ix6fRuyEddjqz1eySWhxkv67MK_kfVOEe4KqzZP8B2cWgcANeA75wBYTh-lcYf3Z1p3-Aq2jKLVemLfS04PsM79LXQdLfpW_y8ayaVPgDJmDPCMvR97nU4hWt7pqPtbTReZqLJ_oSQmm9XzAqbRO_6RofNlMTffA8tvr3_XxcWYFxoWog17gpT2gk2EXh2qcs-yXbU_pvljWD5Ybt-9lPrTTgreSJwbmScmX7VbrcPbKQtTYrWhgHGP4dh63ll6zQLFpZS5ntt3NpjbcV3c8zkRc615Ic2J4_K3hfFAbwhED45xbkdk1t9841dD2Me1QrQQfDpTIInFKjfG2-rSvNCvO-as26iW64gdpOzaVIpaUSNI7LyW10y6HlHVr63EEdVW6h7cOS11Ux9_Y8owE2hytb6OZR0_9vG539yS6vyj3LLo_hL8CUr0tmvVzHK--5-aRh1AtvVHqWT3fRaf_tydExdr04cAYBao3BEWcsh3CWxIqzhPOMxL0E3G8qmIKgQgoBzq0QkeCZIFTFEPZLX8VCESE588kO2iirUt1DHriEVCkS-Ur1ol4uBOEZi0MVcAgFgox00V5jzPTCllxJjVSCJKmxf6rtnya0i540pk7BNvqki5eqmk3TmOo6h2HYRTsWgcVADrAueqoRSd2PeXr1BPfXPf4AbS75_RBt1JOZegTOaS0eGyr9BhZfiDs |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+plasma+6-%5B18F%5Dfluoro-L-3%2C4-dihydroxyphenylalanine+%28%5B18F%5DFdopa%29+in+humans&rft.jtitle=Journal+of+cerebral+blood+flow+and+metabolism&rft.au=Cumming%2C+P&rft.au=L%C3%A9ger%2C+G+C&rft.au=Kuwabara%2C+H&rft.au=Gjedde%2C+A&rft.date=1993-07-01&rft.issn=0271-678X&rft.volume=13&rft.issue=4&rft.spage=668&rft_id=info:doi/10.1038%2Fjcbfm.1993.85&rft_id=info%3Apmid%2F8314919&rft.externalDocID=8314919 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0271-678X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0271-678X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0271-678X&client=summon |